Our site may be slower due to heavy traffic from automated "bots" and AI crawlers. We're working to fix this.

Kelly Fitzgerald, MD

Photo of Kelly Fitzgerald, MD
Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
Address550 16th Street, #6100
San Francisco CA 94158
PronounsShe/Her/Hers
ORCID ORCID Icon0000-0002-7521-0825 Additional info
vCardDownload vCard

    Collapse Biography 
    Collapse education and training
    UCSF, San Francisco, CA06/2017Internal Medicine residency
    Memorial Sloan Kettering Cancer Center, New York, NY06/2023Medical Oncology fellowship

    Collapse Overview 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Stereotactic Body Radiation Therapy With Pembrolizumab in Programmed Cell Death Protein 1 Inhibitor-Refractory Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Phase 2 Trial. Int J Radiat Oncol Biol Phys. 2026 Jan 09. So J, Droznin AD, Tiwari P, Chen YH, Chau NG, Margalit DN, Tishler RB, Hanna GJ, Mak RH, Fitzgerald KJ, Sehgal K, Li S, Gunasti L, Kim E, Minken J, Baginska J, Nau A, Diaz IG, Shim B, Janes JT, Uppaluri R, Haddad RI, Livak KJ, Schoenfeld JD. PMID: 41520892.
      View in: PubMed   Mentions:    Fields:    
    2. Stereotactic magnetic resonance imaging-guided adaptive radiotherapy: a pooled analysis of a master prospective trial. J Natl Cancer Inst. 2025 Nov 01; 117(11):2289-2297. Leeman JE, Shin KY, Droznin A, Catalano P, Cagney DN, Singer L, Oniyangi RD, Zhai K, Benham G, Chirmade S, Campbell J, Boyle S, Saranteas A, Williams CL, Huynh E, Han Z, Sudhyadhom A, Hu YH, Ferguson D, Singhrao K, Hsu SH, Bredfeldt J, Martin NE, Mancias JD, Mamon HJ, Van Dams R, Venkatachalam V, Tanguturi SK, Huynh MA, Fitzgerald KJ, Elhalawani H, Bitterman DS, Schoenfeld JD, Nguyen P, Haas-Kogan DA, Mak R. PMID: 40794880.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    3. Radiomic biomarkers associated with immune checkpoint blockade response for advanced renal cell carcinoma. Urol Oncol. 2025 Dec; 43(12):708.e15-708.e24. Reese SW, Barbakoff D, Ucpinar BA, Knezevic A, Fitzgerald K, Eismann L, Tehrani YM, Arroyave JS, Khaleel S, Khandwala YS, Dawidek M, Motzer RJ, Voss MH, Russo P, Akin O, Kotecha RR, Hakimi AA. PMID: 40914665.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    4. Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94]. Eur Urol. 2025 Jan; 87(1):96. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. PMID: 39426859.
      View in: PubMed   Mentions:    Fields:    
    5. Delta radiomics to track radiation response in lung tumors receiving stereotactic magnetic resonance-guided radiotherapy. Phys Imaging Radiat Oncol. 2024 Jul; 31:100626. Zha Y, Ye Z, Zapaishchykova A, He J, Hsu SH, Leeman JE, Fitzgerald KJ, Kozono DE, Mak RH, Aerts HJWL, Kann BH. PMID: 39253728; PMCID: PMC11381448.
      View in: PubMed   Mentions: 4  
    6. Accuracy, readability, and quality of websites about metastatic renal cell carcinoma treatment. Urol Oncol. 2024 11; 42(11):375.e1-375.e13. Shakhnazaryan N, Gima-Lange L, Desai A, Fitzgerald K, Kwon DH. PMID: 38955572.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    7. Lung sparing in MR-guided non-adaptive SBRT treatment of peripheral lung tumors. Biomed Phys Eng Express. 2024 06 20; 10(4). Lee HY, Lee G, Ferguson D, Hsu SH, Hu YH, Huynh E, Sudhyadhom A, Williams CL, Cagney DN, Fitzgerald KJ, Kann BH, Kozono D, Leeman JE, Mak RH, Han Z. PMID: 38861951.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    8. Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial. Eur Urol. 2024 Aug; 86(2):90-94. Fitzgerald KN, Lee CH, Voss MH, Carlo MI, Knezevic A, Peralta L, Chen Y, Lefkowitz RA, Shah NJ, Owens CN, McHugh DJ, Aggen DH, Laccetti AL, Kotecha RR, Feldman DR, Motzer RJ. PMID: 38782695; PMCID: PMC11970537.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    9. Exploring published and novel pre-treatment CT and PET radiomics to stratify risk of progression among early-stage non-small cell lung cancer patients treated with stereotactic radiation. Radiother Oncol. 2024 01; 190:109983. Thor M, Fitzgerald K, Apte A, Oh JH, Iyer A, Odiase O, Nadeem S, Yorke ED, Chaft J, Wu AJ, Offin M, Simone II CB, Preeshagul I, Gelblum DY, Gomez D, Deasy JO, Rimner A. PMID: 37926331; PMCID: PMC11233189.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    10. Genomic ancestry in kidney cancer: Correlations with clinical and molecular features. Cancer. 2024 03 01; 130(5):692-701. Kotecha RR, Knezevic A, Arora K, Bandlamudi C, Kuo F, Carlo MI, Fitzgerald KN, Feldman DR, Shah NJ, Reznik E, Hakimi AA, Carrot-Zhang J, Mandelker D, Berger M, Lee CH, Motzer RJ, Voss MH. PMID: 37864521; PMCID: PMC11220722.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    11. Pneumonitis in Patients Receiving Thoracic Radiotherapy and Osimertinib: A Multi-Institutional Study. JTO Clin Res Rep. 2023 Oct; 4(10):100559. Banla LI, Tzeng A, Baillieul JP, Kandekhar MJ, Fitzgerald KJ, LoPiccolo J, Poitras HA, Soto DE, Rotow JK, Singer L, Willers H, Kozono DE, Janne PA, Mak RH, Piotrowska Z, Keane FK, Kann BH. PMID: 37732171; PMCID: PMC10507641.
      View in: PubMed   Mentions: 7  
    12. Adjuvant therapy options in renal cell carcinoma - targeting the metastatic cascade. Nat Rev Urol. 2023 03; 20(3):179-193. Fitzgerald KN, Motzer RJ, Lee CH. PMID: 36369389; PMCID: PMC10921989.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    13. Progression-free Survival After Second Line of Therapy for Metastatic Clear Cell Renal Cell Carcinoma in Patients Treated with First-line Immunotherapy Combinations. Eur Urol. 2023 03; 83(3):195-199. Fitzgerald KN, Duzgol C, Knezevic A, Shapnik N, Kotecha R, Aggen DH, Carlo MI, Shah NJ, Voss MH, Feldman DR, Motzer RJ, Lee CH. PMID: 36344318; PMCID: PMC10599591.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    14. Personalizing First-Line Management of Metastatic Renal Cell Carcinoma: Leveraging Current and Novel Therapeutic Options. J Natl Compr Canc Netw. 2022 04 06; 20(13). Fitzgerald KN, Lee CH. PMID: 35385828.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    15. Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas. Eur Urol Focus. 2022 09; 8(5):1278-1288. Yoo A, Tang C, Zucker M, Fitzgerald K, DiNatale RG, Rappold PM, Weiss K, Freeman B, Lee CH, Schultz N, Motzer R, Russo P, Coleman J, Reuter VE, Chen YB, Carlo MI, Gill AJ, Kotecha RR, Ari Hakimi A, Reznik E. PMID: 35288096; PMCID: PMC9464266.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas. Leuk Lymphoma. 2022 03; 63(3):751-754. Fitzgerald KN, Quesada AE, von Keudell G, Raj S, Lewis NE, Dogan A, Salles G, Palomba ML. PMID: 34949132.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    17. Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer. Commun Biol. 2021 11 17; 4(1):1296. Gupta A, Budhu S, Fitzgerald K, Giese R, Michel AO, Holland A, Campesato LF, van Snick J, Uyttenhove C, Ritter G, Wolchok JD, Merghoub T. PMID: 34789823; PMCID: PMC8599839.
      View in: PubMed   Mentions: 8  Translation:Animals
    18. Targeting Phosphatidylserine Enhances the Anti-tumor Response to Tumor-Directed Radiation Therapy in a Preclinical Model of Melanoma. Cell Rep. 2021 01 12; 34(2):108620. Budhu S, Giese R, Gupta A, Fitzgerald K, Zappasodi R, Schad S, Hirschhorn D, Campesato LF, De Henau O, Gigoux M, Liu C, Mazo G, Deng L, Barker CA, Wolchok JD, Merghoub T. PMID: 33440157; PMCID: PMC8100747.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansAnimals
    19. Combining Immunotherapy with Radiation Therapy in Non-Small Cell Lung Cancer. Thorac Surg Clin. 2020 May; 30(2):221-239. Fitzgerald K, Simone CB. PMID: 32327181.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    20. J Clin Oncol. Response to PD-1 inhibition in early- and late-relapsing cutaneous melanoma. 2019; 37:(suppl; abstr e21038). Fitzgerald, K and Daud, A. View Publication.
    21. Systemic therapy for advanced cutaneous squamous cell carcinoma. Semin Cutan Med Surg. 2019 Mar 01; 38(1):E67-E74. Fitzgerald K, Tsai KK. PMID: 31051028.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    22. MYC regulates the antitumor immune response through CD47 and PD-L1. Science. 2016 Apr 08; 352(6282):227-31. Casey SC, Tong L, Li Y, Do R, Walz S, Fitzgerald KN, Gouw AM, Baylot V, Gütgemann I, Eilers M, Felsher DW. PMID: 26966191; PMCID: PMC4940030.
      View in: PubMed   Mentions: 791     Fields:    Translation:HumansAnimalsCells
    23. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015 Jan; 33(1):58-63. Schlaeger TM, Daheron L, Brickler TR, Entwisle S, Chan K, Cianci A, DeVine A, Ettenger A, Fitzgerald K, Godfrey M, Gupta D, McPherson J, Malwadkar P, Gupta M, Bell B, Doi A, Jung N, Li X, Lynes MS, Brookes E, Cherry AB, Demirbas D, Tsankov AM, Zon LI, Rubin LL, Feinberg AP, Meissner A, Cowan CA, Daley GQ. PMID: 25437882; PMCID: PMC4329913.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansCells
    Kelly's Networks
    Concepts (87)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (5)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-21-g9d46e6c4 on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.